Last reviewed · How we verify
Anise-oil EC Capsule
Anise oil acts as a carminative and anti-inflammatory agent that reduces gastrointestinal distension and promotes digestive comfort through its volatile oil constituents.
Anise oil acts as a carminative and anti-inflammatory agent that reduces gastrointestinal distension and promotes digestive comfort through its volatile oil constituents. Used for Functional dyspepsia, Irritable bowel syndrome, Bloating and abdominal distension.
At a glance
| Generic name | Anise-oil EC Capsule |
|---|---|
| Also known as | Group A |
| Sponsor | Shiraz University of Medical Sciences |
| Drug class | Herbal carminative / digestive aid |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Anise oil contains anethole and other volatile compounds that relax smooth muscle in the gastrointestinal tract, reduce gas formation, and possess antimicrobial and anti-inflammatory properties. These effects collectively improve digestive symptoms and gastrointestinal motility. The enteric coating (EC) formulation allows targeted delivery to the small intestine for enhanced therapeutic effect.
Approved indications
- Functional dyspepsia
- Irritable bowel syndrome
- Bloating and abdominal distension
Common side effects
- Allergic reactions (anise sensitivity)
- Gastrointestinal upset
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anise-oil EC Capsule CI brief — competitive landscape report
- Anise-oil EC Capsule updates RSS · CI watch RSS
- Shiraz University of Medical Sciences portfolio CI